SCHEMBL3935672

SCHEMBL3935672

CN(C)CCN(c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccc3[nH]c(=O)oc3c2)cc1)S(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.38
POLB P06746 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
KMT2A Q03164 2/20 0.35
CREBBP Q92793 1/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ATXN2 Q99700 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3935382 0.94 LMNA (0.35) ALPLPOLBTDP1GAAMAPT
SCHEMBL3936297 0.88 CREBBP (0.38) ALPLPOLBTDP1GAAMAPT
SCHEMBL3935892 0.86 CREBBP (0.39) ALPLPOLBTDP1GAAMAPT
SCHEMBL3933165 0.86 CREBBP (0.38) ALPLPOLBTDP1KMT2ACREBBP
SCHEMBL3933015 0.85 PKM (0.38) POLBTDP1MAPTKMT2AMEN1
SCHEMBL3933023 0.85 CREBBP (0.36) ALPLPOLBTDP1GAAMAPT
SCHEMBL3930885 0.84 CREBBP (0.39) ALPLPOLBTDP1GAAMAPT
SCHEMBL3935943 0.84 MEN1 (0.35) MAPTKMT2AMEN1RAB9AKDM4E
SCHEMBL4494272 0.84 GAA (0.38) POLBGAAMAPTKMT2AMEN1
SCHEMBL4494278 0.84 GAA (0.38) POLBGAAMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 ALPL 1300/4885POLB 1516/4885TDP1 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.